<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045638</url>
  </required_header>
  <id_info>
    <org_study_id>20200426</org_study_id>
    <nct_id>NCT05045638</nct_id>
  </id_info>
  <brief_title>Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants</brief_title>
  <official_title>A Phase I, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin, a Breast Cancer Resistance Protein Substrate, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin,&#xD;
      and to assess the PK of rosuvastatin when administered alone, in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Actual">October 10, 2021</completion_date>
  <primary_completion_date type="Actual">October 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Rosuvastatin</measure>
    <time_frame>Day 1 to Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rosuvastatin</measure>
    <time_frame>Day 1 to Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from Time Zero to Infinity (AUCinf) of Rosuvastatin</measure>
    <time_frame>Day 1 to Day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting any Adverse Events</measure>
    <time_frame>36 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormal Changes from Baseline in Clinical Laboratory Tests</measure>
    <time_frame>Baseline (Day 1) to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormal Changes from Baseline in 12-Leads Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline (screening) to Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormal Changes from Baseline in Vital Signs</measure>
    <time_frame>Baseline (Day 1) to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Sotorasib</measure>
    <time_frame>Day 6 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of Sotorasib</measure>
    <time_frame>Day 6 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Sotorasib</measure>
    <time_frame>Day 6 to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin + sotorasib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Rosuvastatin + sotorasib</arm_group_label>
    <arm_group_label>Rosuvastatin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotorasib</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Rosuvastatin + sotorasib</arm_group_label>
    <other_name>AMG 510</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male subjects or female subjects, between 18 and 60 years of age (inclusive),&#xD;
             at the time of Screening.&#xD;
&#xD;
          -  Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening.&#xD;
&#xD;
          -  Females of nonchildbearing potential&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Inability to swallow oral medication or history of malabsorption syndrome.&#xD;
&#xD;
          -  History of hypersensitivity, intolerance, or allergy to any drug compound, food, or&#xD;
             other substance, unless approved by the Investigator (or designee) and in consultation&#xD;
             with the Sponsor.&#xD;
&#xD;
          -  Poor peripheral venous access.&#xD;
&#xD;
          -  History or evidence, at Screening or Check in, of clinically significant disorder,&#xD;
             condition, or disease, including history of myolysis, not otherwise excluded that, in&#xD;
             the opinion of the Investigator (or designee), would pose a risk to subject safety or&#xD;
             interfere with the study evaluation, procedures, or completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit - Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117-5116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 510</keyword>
  <keyword>Sotorasib</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Healthy participants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

